Dr. Ian Wilson received a B.Sc. in Biochemistry from the University of Edinburgh, a D. Phil. in Molecular Biophysics from Oxford University, and did postdoctoral research at Harvard University. Dr. Wilson has been a Professor at The Scripps Research Institute since 1982 and is Hansen Professor of Structural Biology and Chair of the Department of Integrative Structural and Computational Biology. His laboratory focuses on immune recognition and, in particular, on how pathogens are recognized by the adaptive and innate immune systems. Dr. Wilson also directed the Joint Center for Structural Genomics (JCSG) from 2000-2016. The JCSG pioneered new methods for high-throughput structural studies, including x-ray and NMR, and determined 1600 novel structures in the NIH NIGMS Protein Structure Initiative. Dr. Wilson is a Fellow of the Royal Society, Corresponding Fellow of the Royal Society of Edinburgh, Member of the American Academy of Arts and Sciences, Honorary Fellow of Corpus Christi College, Oxford, and was awarded a D.Sc. from Oxford University 2000. He is on the Statistical Board of Reviewing Editors for Science, the Editorial Board of Cell, and the Board of Directors for Keystone Symposia. He has published more than 680 papers. Research Interests Dr. Wilson’s laboratory focuses on recognition of microbial pathogens by the adaptive and innate immune systems. His laboratory has determined crystal structures of many different immune receptors, including antibodies (>250) with a variety of antigens, MHC class I and class II complexes, CD1, T cell receptors, cytokine receptors, Toll­‐like receptors (TLRs), variable lymphocyte receptors (VLRs), and other key pattern recognition receptors. His current focus is on defining sites of vulnerability on viral pathogens through structural characterization of the interaction of human broadly neutralizing antibodies with viral antigens, particularly for HIV­‐1, influenza virus, and HCV. His lab also recently determined crystal structures of the HIV-1 gp140 envelope and HCV E2 surface glycoproteins as well as hemagglutinin glycoproteins from emerging influenza viruses, including H1, H5, H6, H7 and H10 subtypes. A related research focus is on understanding the structural basis of how avian and other zoonotic influenza viruses adapt to human hosts and cross the species barrier by changing their receptor specificity. A major driving force and goal of these projects is structure­‐based design of new vaccines and therapeutics.